#KarimFizazi with final OS analysis of #PEACE1 in met hormone sensitive prostate cancer treated w abiraterone +/- XRT, and +/- docetaxel. Important OS benefit across all subsets, m

Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky)· @TiansterZhang · X·2026-10-24 16:33· 23 小时前评分70

正文 · 机器翻译

#KarimFizazi 介绍了 #PEACE1 在转移性激素敏感性前列腺癌中的最终 OS 分析，患儿接受 abiraterone 联合或不联合 XRT，并联合或不联合 docetaxel 治疗。所有亚组均获得显著 OS 获益，中位生存期为 6.1 年。
@oncoalert @myESMO #ESMO26

139 浏览 · 7 赞 · 6 转发 · 0 回复

会议摘要

2300TIPNCT07365995 NCT07365995 NCT07365995按 Metastatic prostate cancer 对上

BNT324-03: A phase 3, randomized, open-label trial comparing elfetabart drozuntecan, a B7H3 antibody-drug conjugate, with investigator's choice of docetaxel or cabazitaxel in patients with metastatic castration-resistant prostate cancer

https://esmocongress.esmo.org

LBA15按 Proffered paper 2: Breast cancer, early and advanced stage 对上

Anbenitamab plus albumin-bound docetaxel in patients (pts) with HER2-positive advanced breast cancer (BC): A randomized phase III study

https://esmocongress.esmo.org

NCT04884282NCT04884282按 - **标题 / Title：** Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED) 对上

- **标题 / Title：** Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)

https://esmocongress.esmo.org

来源：Tian Zhang, MD, MHS, FASCO (@tiansterzhangmd.bsky) · x.com